Inotiv Inc. (NASDAQ: NOTV) Stock Information | RedChip

Inotiv Inc. (NASDAQ: NOTV) Listen to this Section


$1.57
+0.0350 ( +2.29% ) 74.0K

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.

Market Data


Open


$1.57

Previous close


$1.53

Volume


74.0K

Market cap


$40.83M

Day range


$1.52 - $1.59

52 week range


$1.49 - $11.42

Insider Ownership Transactions

Total Amount Purchased: -23,909.00 | $ -37,417.59

Date Type Amount Purchased Purchaser
2024-08-14 Sale -27500.00 Harrington Michael J
2024-08-14 Sale -27500.00 Brown Nigel
2024-01-25 Buy 7500.00 Leasure Robert Jr.
2024-01-16 Sale -10000.00 Castetter Andrea
2024-01-10 Sale -2500.00 Beraldi Fernanda
2023-12-15 Sale -6250.00 Sagartz John E
2023-12-15 Sale -4375.00 Freeman Jeffrey Brennan
2023-12-15 Sale -6250.00 Taylor Beth
2023-12-15 Buy 5000.00 Garrett Michael
2023-12-15 Buy 47966.00 Beattie John Gregory

SEC Fillings


Form Type Description Pages Date
4 Insider transactions 1 Aug 14, 2024
4 Insider transactions 1 Aug 14, 2024
4 Insider transactions 1 Aug 14, 2024
8-k 8K-related 17 Aug 09, 2024
10-q Quarterly Reports 89 Aug 09, 2024
8-k 8K-related 14 Aug 08, 2024
3 Insider transactions 2 Jun 10, 2024
8-k 8K-related 17 Jun 04, 2024
10-q/a Quarterly Reports 85 May 16, 2024
10-q Quarterly Reports 87 May 15, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.